Levin Papantonio Litigation News | Levin Papantonio | Personal Injury Lawyers & Accident Attorneys

Monsanto Gets Continued Government Approval for its Carcinogen Roundup Using Studies Paid for by Monsanto

Last year, the International Agency for Research on Cancer (IARC), part of the World Health Organization (WHO), determined that glyphosate, the active ingredient in Monsanto's herbicide Roundup®, is a likely carcinogen.  This finding has been reinforced by numerous scientific studies demonstrating that glyphosate has a detrimental effect on the human endocrine system (which produces and regulates hormones). This, in turn, can lead to the development of certain types of cancer, particularly of the lymph nodes.

read more

Nexium and Prilosec: an Addiction Hard to Kick and Causing Kidney Disease

By now, news of the connection between the use of proton pump inhibitors (PPIs) on patients and serious kidney damage has spread widely. Investigation into PPI drugs that include Prilosec and Nexium has just begun, although other safety concerns about PPIs (involving the elevated risk of heart attacks and osteoporosis) were first raised over a decade ago.

read more

Talcum Powder and the Ovarian Cancer Connection

Talcum powder, a seemingly innocuous substance, has been used by women for various personal and household purposes for well over a century. Suddenly, it is now a cause of action by hundreds of plaintiffs who allege a connection between the use of talcum powder and cancer. Why?

read more

Taxotere -- The Permanent Hair Loss Side Effect

Taxotere (docetaxel) is a chemotherapy drug that is part of the class known as taxanes. This class also includes Taxol (paclitaxel). Both drugs are mitotic inhibitors, meaning that they interfere with the process of mitosis, or cell division.  Although these drugs are intended to target malignant cancer cells, they do affect the reproduction of other cells as well – including hair follicles. This is the reason that cancer patients undergoing chemotherapy suffer hair loss.

read more

Giant Killers: Inside Mass Torts

This story was originally published on InWeekly and features a profile on one of our primary hosts Mike Papantonio, America’s Lawyer, discussing the many accomplishments of the law firm Levin Papantonio.

read more

NBC News Asked the Important Question: Why Did Bard Continue Selling a Dangerously Defective Medical Device?

NBC News may be a bit behind the curve, but at least the question has now been posed to the general public. Medical device manufacturer C.R. Bard continued to market and sell a product that was known to be defective, resulting in nearly 30 deaths and hundreds of serious injuries. Furthermore, there is strong evidence that Bard was willing to commit criminal fraud in order to keep the product on the market. The question now being asked is: why?

read more

FDA Finally Issues Warning About Invokana and Ketoacidosis: Why Did It Take So Long?

On December 4, 2015, the U.S. Food and Drug Administration finally updated a safety announcement, first issued the previous May, about the serious side effects of a recently-approved class of diabetic “wonder drugs.” The medications of that class are known as gliflozins, or “sodium-glucose cotransporter-2 (SGLT-2) inhibitors”, the best known being Invokana. The specific side effect addressed in the warning is a condition known as ketoacidosis, in which the blood becomes dangerously acidic.

read more

Puerto Rico Bond Securities Fraud: Banco Santander Under Fire

Less than a month after UBS Puerto Rico was ordered to pay $34 million in order to settle charges of fraud in connection with the sale of Puerto Rico municipal bonds, another giant financial institution has been fined by the Financial Institution Regulatory Authority (FINRA) over nearly identical allegations.  Like those at UBS, financial advisers at Banco Santander's Puerto Rico division steered their clients into investments concentrated in high-risk Puerto Rican securities at the same time that said bonds were falling precipitously in value.

read more

Failure to File Safety Reports Costs Fiat-Chrysler Big Bucks

On top of numerous recalls involving 11 million vehicles this year alone, Fiat-Chrysler Automobiles (FCA) has been found to be in violation of federal regulations, requiring automakers to report on safety issues with the vehicles they produce to the National Highway Traffic Safety Administration (NHTSA). As a result, the company will wind up paying a fine in the amount of $70 million to the federal government.

read more